S100A11 and neoplasm: Simultaneously, abnormal AKT and ERK1/2 phosphorylation in HCC are hallmarks of tumor progression 29, 30, another promising finding in our study was that S100A11 knockdown inhibits AKT and ERK1/2 phosphorylation, which suggests that S100A11 is involved in the activation of AKT and ERK signaling pathways.